• New immunotherapy drug becomes first ever to DOUBLE survival in lung cancer patients

    5 monthes ago - By Daily Mail

    Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year.
    Read more ...

     

  • Immunotherapy-chemotherapy combination extends survival in newly diagnosed metastatic lung cancer

    Immunotherapy-chemotherapy combination extends survival in newly diagnosed metastatic lung cancer

    5 monthes ago - By Healio

    Leena Gandhi
    CHICAGO - The addition of the anti-PD-1 therapy pembrolizumab to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who do not harbor EGFR or ALK alterations, according to results of the randomized phase 3 KEYNOTE-189 trial presented at American Association for Cancer Research Annual Meeting.
    Trial results showed improvements in PFS, OS and overall response rate among all patient groups, halving the risk for death and demonstrating “an unprecedented effect of therapy in the first-line setting”
    Read more ...

     

  • Immunotherapy superior to chemotherapy for advanced lung cancer with high tumor mutational burden

    5 monthes ago - By Healio

    Matthew Hellmann
    CHICAGO - Immunotherapy with nivolumab plus ipilimumab significantly prolonged PFS compared with standard chemotherapy among patients with newly diagnosed advanced non-small cell lung cancer with high tumor mutational burden, according to results of the randomized phase 3 CheckMate -227 trial presented at American Association for Cancer Research Annual Meeting.
    The study offers the opportunity to introduce two new standards of care for patients with non-small cell lung cancer, according to researcher Matthew Hellmann, MD, assistant attending at Memorial Sloan Kettering
    Read more ...